PlasmaBound raises funding to accelerate bonding technology adaptation

2023-01-23
Pictured left to right at NovaUCD are PlasmaBound founders, Dr James Nicholas Barry, Alan Barry and Xavier Montibert. Photo Credit: PlasmaBound Irish startup PlasmaBound (Dublin) secured a €750,000 investment from Business Venture Partners (BVP) in December 2022, in addition to previous funding from Act Venture Capital, Atlantic Bridge and Enterprise Ireland. This brings total funding to €3.1 million, which will be used to advance PlasmaBound’s vision to make lightweight composite materials affordable for low- to mid-range vehicles. PlasmaBound has developed controlled polymer ablation (CPA), an environmentally friendly, high-speed and low-cost bonding technology for composite materials. The company anticipates that its technology will help move the drive toward lower CO2 emissions and longer electric vehicle (EV) range into mass-market applications. PlasmaBound, a University College Dublin (UCD) spin-out company, was co-founded in 2017 by Dr. James Nicholas Barry, Alan Barry and Xavier Montibert. It was recently selected as one of five startups to win access to the Hyundai Motor Co. and KIA Corp. sponsored 2022 Accelerate the Future Challenge. PlasmaBound is headquartered at NovaUCD. “We are delighted to have secured this investment from BVP. It will help PlasmaBound bring about a further positive impact to the environment with the adaption of our CPA technology in manufacturing process throughout various sectors, with a particular focus on automotive, aerospace and space, along with consumer electronics, and sports and eisure,” Alan Barry, CEO, PlasmaBound, says.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。